Patents Issued in July 25, 2024
  • Publication number: 20240245686
    Abstract: The present invention provides combination therapy that includes an KRASG12C inhibitor, such as or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: December 19, 2023
    Publication date: July 25, 2024
    Applicant: Amgen Inc.
    Inventors: James Russell LIPFORD, Jude Robert CANON, Anne Y. SAIKI, Karen Louise REX
  • Publication number: 20240245687
    Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
    Type: Application
    Filed: February 27, 2024
    Publication date: July 25, 2024
    Inventors: Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
  • Publication number: 20240245688
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
    Type: Application
    Filed: April 2, 2024
    Publication date: July 25, 2024
    Applicant: LIQMEDS WORLDWIDE LIMITED
    Inventors: Jinal PANDYA, Sandip P. MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL, Hiren PANSURIYA
  • Publication number: 20240245689
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
    Type: Application
    Filed: April 4, 2024
    Publication date: July 25, 2024
    Applicant: LIQMEDS WORLDWIDE LIMITED
    Inventors: Jinal PANDYA, Sandip P. MEHTA, Manish UMRETHIA, Jayanta Kumar MANDAL, Hiren PANSURIYA
  • Publication number: 20240245690
    Abstract: The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs.
    Type: Application
    Filed: April 4, 2024
    Publication date: July 25, 2024
    Inventors: Alastair Stewart, Christine Keenan, Trudi Harris
  • Publication number: 20240245691
    Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein RA, RZ, RC, RD, RF and RG are as defined herein.
    Type: Application
    Filed: April 26, 2022
    Publication date: July 25, 2024
    Applicant: Sitryx Therapeutics Limited
    Inventors: Matthew Colin Thor FYFE, Michael Liam COOKE, David COUSIN, Saleh AHMED, Alessandro MAZZACANI
  • Publication number: 20240245692
    Abstract: A pharmaceutical composition containing a compound of Formula 1 or Formula 2 below or a pharmaceutically acceptable salt thereof. The composition is suitable for preventing or treating RON-mutation-associated biliary tract cancer. The pharmaceutical composition can be applied to a biliary tract cancer patient having a RON mutation. Particularly, the pharmaceutical composition can be effectively used for treating a biliary tract cancer patient who is resistant to cetuximab, which is conventionally used for cancer treatment, and who has mutation at RONA 155, RON?160 or RON?165.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 25, 2024
    Applicant: WELLMARKER BIO CO., LTD.
    Inventors: Seung-Mi KIM, Yeon-Seoung CHOI, Ha-Neul LEE, Ji-Hyun GO, Eun-Hee KO, Yu-Geun JI
  • Publication number: 20240245693
    Abstract: Using a reversed-phase high-performance liquid chromatographic (HPLC) technique, a mixture of antimycins A was separated into eight hitherto unreported subcomponents, Ala, Alb, A2a, A2b, A3a, A3b, Ma, and A4b. Although a base-line resolution of the known four major antimycins Al, A2, A3, and A4 was readily achieved with mobile phases containing acetate buffers, the separation of the new antibiotic subcomponents was highly sensitive to variation in mobile phase conditions. The type and composition of organic modifiers, the nature of buffer salts, and the concentration of added electrolytes had profound effects on capacity factors, separation factors, and peak resolution values. Of the numerous chromatographic systems examined, a mobile phase consisting of methanol-water (70:30) and 0.005 M tetrabutylammonium phosphate at pH 3.0 yielded the most satisfactory results for the separation of the subcomponents.
    Type: Application
    Filed: May 20, 2022
    Publication date: July 25, 2024
    Applicant: The Regents of the University of California
    Inventors: Ichiro NISHIMURA, Akishige HOKUGO, Takeru KONDO, Yoichiro SHIBUYA
  • Publication number: 20240245694
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
    Type: Application
    Filed: October 10, 2023
    Publication date: July 25, 2024
    Inventors: Vincent BORDAS, Markus FUREGATI, Jacques HAMON, Jürgen Hans-Hermann HINRICHS, Ziyue HONG, Fabio LIMA, Fatma LIMAM, Henrik MOEBITZ, Sandro NOCITO, Niko SCHMIEDEBERG, Joseph SCHOEPFER, Ross Sinclair STRANG, Frédéric ZECRI, Huangchao YU, Yong ZHANG, Xinkan YANG, Sisi ZHANG, Wei LI
  • Publication number: 20240245695
    Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: November 29, 2023
    Publication date: July 25, 2024
    Applicants: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
  • Publication number: 20240245696
    Abstract: The present disclosure relates to compositions and methods for improving the transplantation outcome and/or reducing immune response in a subject. The compositions comprise a DNA-PK inhibitor.
    Type: Application
    Filed: February 21, 2024
    Publication date: July 25, 2024
    Inventors: Lyle Burdine, Marie Burdine, Ara Kim Wiese
  • Publication number: 20240245697
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 25, 2024
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J.N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • Publication number: 20240245698
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 25, 2024
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J.N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • Publication number: 20240245699
    Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    Type: Application
    Filed: February 29, 2024
    Publication date: July 25, 2024
    Inventors: Arnaud LE TIRAN, Thierry LE DIGUARHER, Jérôme-Benoît STARCK, Jean-Michel HENLIN, Anne-Françoise GUILLOUZIC, Guillaume DE NANTEUIL, Olivier GENESTE, Imre FEJES, János TATAI, Miklós NYERGES, James Edward Paul DAVIDSON, James Brooke MURRAY, I-Jen CHEN, Didier DURAND
  • Publication number: 20240245700
    Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4 alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4 alkyl; C2-4 alkenyl; and halogenated C1-4 alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.
    Type: Application
    Filed: March 5, 2024
    Publication date: July 25, 2024
    Applicant: WisTa Laboratories Ltd.
    Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Rober Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
  • Publication number: 20240245701
    Abstract: This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.
    Type: Application
    Filed: September 1, 2023
    Publication date: July 25, 2024
    Inventor: Sara P. Cotter
  • Publication number: 20240245702
    Abstract: Methods for the generation of sensorineural hair cells, and more particularly to the use of epigenetic modulation of Atoh1 expression using a combination of Histone Lysine Demethylase (KDM) inhibitors and Wnt activators to generate sensorineural hair cells.
    Type: Application
    Filed: October 20, 2023
    Publication date: July 25, 2024
    Inventors: Albert Edge, Niliksha Gunewardene
  • Publication number: 20240245703
    Abstract: A skin protective composition includes at least one functional inhibitor of an acid sphingomyelinase (FIASM) in a dermatologically acceptable carrier. A method of ameliorating photosensitivity in a subject includes topically administering the skin protective composition to a subject, where the therapeutically effective amount is demonstrated to reduce or eliminate inflammation, microvesicle particle release, erythema, or a combination thereof. In another embodiment, a method inhibits the release of microvesicle particles from skin cells. In another embodiment, a method reduces side effects resulting from a topical photodynamic therapy treatment.
    Type: Application
    Filed: April 1, 2024
    Publication date: July 25, 2024
    Inventor: Jeffrey B. TRAVERS
  • Publication number: 20240245704
    Abstract: A pharmaceutical composition and use of a multi-kinase inhibitor. The present invention relates to the technical field of medicines, and relates to the pharmaceutical composition and use of the multi-kinase inhibitor. The pharmaceutical composition comprises: (a) a compound represented by general formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a crystal form thereof, wherein P1, W1, Y1, and Ar in general formula (I) are as described herein; and (b) a paclitaxel drug. Variables in the general formula are as defined in the description. Studies have shown that the compound of general formula (I) or the pharmaceutically acceptable salt, stereoisomer or crystal form thereof in the present invention has a significant synergistic interaction with the paclitaxel drug in combination for treating cancers.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 25, 2024
    Applicant: TRANSTHERA SCIENCES (NANJING), INC.
    Inventors: Peng PENG, Xiaoyan QIANG, Caixia SUN, Hui WANG, Qi YU
  • Publication number: 20240245705
    Abstract: Pharmaceutical compositions comprise amoxicillin and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of amoxicillin and avibactam in the plasma of a patient. The oral pharmaceutical compositions and methods can be used to treat mycobacterial infections.
    Type: Application
    Filed: March 27, 2024
    Publication date: July 25, 2024
    Applicant: Arixa Pharmaceuticals, Inc.
    Inventor: JOAQUIM TRIAS
  • Publication number: 20240245706
    Abstract: Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterized by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.
    Type: Application
    Filed: December 19, 2023
    Publication date: July 25, 2024
    Inventors: Iain Stewart MCGREGOR, Michael KASSIOU, Michael Thomas BOWEN, Callum HICKS, William JORGENSEN
  • Publication number: 20240245707
    Abstract: It provides methods and compositions for treating insomnia comprising administering a composition comprising a compound of formula A or formula I (e.g., anordrin) or a pharmaceutically acceptable salt or ester thereof. In some embodiments, the compound is anordrin.
    Type: Application
    Filed: May 23, 2022
    Publication date: July 25, 2024
    Inventor: Jun YANG
  • Publication number: 20240245708
    Abstract: Disclosed are pharmaceutical compositions and oral dosage forms including capsules containing (17-?)-3-oxoandrost-4-en-17-yl tridecanoate, and related methods. The capsule fill can include an additive and about 14 wt % to about 42 wt % for androst-4-en-17?-ol-3-one esters that comprise (17-?)-3-oxoandrost-4-en-17-yl tridecanoate or a combination of (17-?)-3-oxoandrost-4-en-17-yl undecanoate, (17-?)-3-oxoandrost-4-en-17-yl dodecanoate, and (17-?)-3-oxoandrost-4-en-17-yl tridecanoate. A single oral administration to a male subject of one or more dosage forms with a total androst-4-en-17?-ol-3-one equivalent dose of about 150 mg to about 895 mg is provided. In another embodiment, a method for providing a serum concentration of androst-4-en-17?-ol-3-one within a target PK performance for a male subject is provided.
    Type: Application
    Filed: February 9, 2024
    Publication date: July 25, 2024
    Applicant: Lipocine Inc.
    Inventors: Kilyoung Kim, Mahesh V. Patel, Nachiappan Chidambaram
  • Publication number: 20240245709
    Abstract: This invention relates to methods for treating established status epilepticus (ESE) by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides ESE suppression and continued suppression of ESE.
    Type: Application
    Filed: April 3, 2024
    Publication date: July 25, 2024
    Inventors: Henrikas VAITKEVICIUS, Maciej Gasior, Joseph Hulihan
  • Publication number: 20240245710
    Abstract: Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.
    Type: Application
    Filed: February 1, 2024
    Publication date: July 25, 2024
    Inventors: Linda Anne Snyder, Margaret K. Yu
  • Publication number: 20240245711
    Abstract: The present disclosure relates to methods of treating major depressive disorder (MDD) in a subject in need thereof by (i) performing an initial treatment course on the subject comprising administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, and (ii) performing 0, 1, or 2 subsequent treatment courses on the subject, wherein each subsequent treatment course comprises administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, in response to a recurrence of depression symptoms. The 0, 1, or 2 subsequent treatment courses can be performed over a period of 12 months from the beginning of the initial treatment course.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 25, 2024
    Inventors: Robert Alfonso Lasser, James Doherty, Jeffrey Martin Jonas, Stephen Jay Kanes, Handan Gunduz-Bruce, Joi Lisa Dunbar, Bambang Senoaji Adiwijaya
  • Publication number: 20240245712
    Abstract: This document relates to methods and materials involved in identifying and/or treating mammals having membranous nephropathy (e.g., membranous nephropathy with an elevated level of a neuron-derived neurotrophic factor (NDNF) polypeptide in the glomerular basement membrane (GBM)). For example, methods and materials for administering one or more antimicrobial agents to treat a mammal (e.g., a human) having membranous nephropathy are provided.
    Type: Application
    Filed: January 16, 2024
    Publication date: July 25, 2024
    Inventors: Sanjeev Sethi, Fernando C. Fervenza, Benjamin J. Madden
  • Publication number: 20240245713
    Abstract: Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection.
    Type: Application
    Filed: April 3, 2024
    Publication date: July 25, 2024
    Inventors: Gail L. Dempsey, Douglas I. Hepler, Dorothea Erxleben, Michael S. Daniel, Neil E. Paulsen
  • Publication number: 20240245714
    Abstract: Compositions and methods that use a combination of NARH and NR to produce intracellular NAD+/NADH. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to an individual to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (“NAD+”) in cells and tissues for improving cell and tissue survival or overall cell and tissue health. Also, the compositions can be administered to an individual to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g.
    Type: Application
    Filed: April 25, 2022
    Publication date: July 25, 2024
    Inventors: CARLES CANTO ALVAREZ, ELEONORA CIARLO, MARIA PILAR GINER, SOFIA MOCO
  • Publication number: 20240245715
    Abstract: The present disclosure provides a pharmaceutical composition comprising i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic. Kits utilizing i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic are also provided, as well as methods utilizing the described pharmaceutical compositions and kits.
    Type: Application
    Filed: February 15, 2024
    Publication date: July 25, 2024
    Inventors: Bernard LAUGHLIN, Kelly DREW
  • Publication number: 20240245716
    Abstract: Disclosed herein are adenosine derivative prodrugs and compositions thereof that can be used for the treatment of HIV infection or RNA virus infection.
    Type: Application
    Filed: September 15, 2023
    Publication date: July 25, 2024
    Inventor: Lianhong XU
  • Publication number: 20240245717
    Abstract: Antiviral compounds and compositions of Formula (I) and methods of use are disclosed.
    Type: Application
    Filed: December 14, 2023
    Publication date: July 25, 2024
    Inventors: Kelvin Cooper, Steven Parkinson
  • Publication number: 20240245718
    Abstract: Medium molecular weight heparin for use in the treatment of disease, specifically, in the treatment of endotheliopathy in a patient having a plasma von Willebrand factor antigen to ADAMTS13 ratio of at least about 2. Also, a pharmaceutical formulation and a kit comprising a medium molecular weight heparin, and a method of treating endotheliopathy, comprising administering to a patient in need of treatment a therapeutically effective amount of medium molecular weight heparin, wherein the patient has a plasma von Willebrand factor antigen to ADAMTS13 ratio of at least about 2.
    Type: Application
    Filed: May 16, 2022
    Publication date: July 25, 2024
    Applicant: GLYCOS BIOMEDICAL LTD
    Inventor: Pervinder Singh Bhogal
  • Publication number: 20240245719
    Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated poly-styrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.
    Type: Application
    Filed: June 6, 2023
    Publication date: July 25, 2024
    Inventors: Daniel R. GETTS, Rachael TERRY, Nicholas KING
  • Publication number: 20240245720
    Abstract: The present disclosure provides a composition comprising an extracellular vesicle (EV) associated with an active agent and a polymer, wherein said polymer carries at least one positively charged moiety or has at least one positive pole and said active agent carries, independently, at least one negatively charged moiety or has at least one negative pole; and wherein said polymer and said active agent are present at a positive to negative charge or pole ratio of at least 2. A preferred example relates to a composition wherein the polymer is polyethyleneimine, the agent is a nucleic acid and the EV is an exosome. The present disclosure also provides methods for obtaining the composition and uses of the composition.
    Type: Application
    Filed: May 25, 2022
    Publication date: July 25, 2024
    Inventors: Daniel OFFEN, Nataly YOM-TOV
  • Publication number: 20240245721
    Abstract: Disclosed are chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNP) compositions and methods of using the same for delivering therapeutics to a particular target.
    Type: Application
    Filed: May 5, 2022
    Publication date: July 25, 2024
    Inventors: Kytai NGUYEN, Jon WEIDANZ, Serkan YAMAN, Harish RAMACHANDRAMOORTHY, Manoj Kumar SABNANI
  • Publication number: 20240245722
    Abstract: The present invention relates to a monobody-based chimeric antigen receptor. The monobody-based chimeric antigen receptor possesses an extracellular ligand binding domain comprising a monobody. In addition, the present invention relates to an immune cell having the monobody-based chimeric antigen receptor expressed on the cell surface membrane thereof. Such monobody-based CAR-immune cells 1) can target a receptor expressed on the surface of cancer cells to exhibit an excellent prophylactic or therapeutic effect on cancer, 2) when administered into humans, exhibit low immunogenicity because they use a human FN3-based monobody as an extracellular ligand binding domain, as opposed to animal-derived scFv-based CAR-immune cells, 3) are of high infiltration into tissues due to their smaller sizes than those of scFV, 4) can minimize the side effects that conventional antibody cancer therapy possesses (e.g.
    Type: Application
    Filed: May 24, 2022
    Publication date: July 25, 2024
    Inventor: Joon Haeng RHEE
  • Publication number: 20240245723
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 23, 2024
    Publication date: July 25, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • Publication number: 20240245724
    Abstract: Apparatus, kit and method embodiments are disclosed herein that provide for the production of a modified autologous platelet mixture at a patient bedside for contemporaneous reinjection to the patient using a platelet lysis apparatus. Representative platelet lysis apparatus may include a housing supporting a sample tube and a thermal mass element connected to or near the sample tube. The thermal mass element may be separable from the housing, and/or the sample tube may be separable from the thermal mass element.
    Type: Application
    Filed: January 17, 2024
    Publication date: July 25, 2024
    Inventors: Christopher J. Centeno, Neven Steinmetz, Ian Stemper, Dustin Berger
  • Publication number: 20240245725
    Abstract: Provided herein are methods and compositions for improving safety and efficacy of hemoglobinopathy treatment by assessing the presence or absence of a given SNP polymorphism that affects CRISPR/Cas mediated reinduction of fetal hemoglobin (i.e., ?-globin) in a cell by disrupting BCL11A expression at the genomic level.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 25, 2024
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Daniel E. BAUER
  • Publication number: 20240245726
    Abstract: The present invention relates to compositions comprising integrin ?10-selectedMesenchymal Stem Cells (MSCs) for use in treatment and/or regeneration of a skin defect.
    Type: Application
    Filed: May 20, 2022
    Publication date: July 25, 2024
    Inventors: Evy Lundgren Åkerlund, Folke Sjöberg, Hooi Ching Lim, Ahmed Elserafy, Moustafa Elmasry
  • Publication number: 20240245727
    Abstract: The present disclosure relates to a cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs) expressing CD13 and CD44 and methods of treating a neurological disease or condition comprising systemically administering to a subject a cryopreserved pharmaceutical composition comprising IDPSCs expressing CD13 and CD44. In some aspects, the IDPSCs in the cryopreserved pharmaceutical composition described herein further expresses beta-3-tubulin. In some aspects, the IDPSCs secrete brain-derived neurotrophic factor.
    Type: Application
    Filed: March 13, 2024
    Publication date: July 25, 2024
    Inventors: Irina Kerkis, Alexandre Kerkis
  • Publication number: 20240245728
    Abstract: Provided herein are living scaffolds for peripheral nerve regeneration, the living scaffolds including tissue engineered nerve grafts (TENGs) programmed to express neurogenic growth factors with temporal and spatial control. Further provided herein are compositions and methods for facilitating nerve regeneration, such as compositions and methods comprising TENGs modified to express a neurotrophic growth factor.
    Type: Application
    Filed: January 19, 2024
    Publication date: July 25, 2024
    Inventors: Daniel Kacy Cullen, Hannah Hoeun Lee, Robert Shultz, Sam Lien
  • Publication number: 20240245729
    Abstract: The present disclosure encompasses methods for priming an allogeneic cultured keratinocyte composition for topical use.
    Type: Application
    Filed: May 27, 2022
    Publication date: July 25, 2024
    Inventors: Allen R. Comer, Kenneth R. Gratz
  • Publication number: 20240245730
    Abstract: The present invention provides fusion proteins that induce local immune tolerance. The fusion proteins comprise peptides derived the immunoregulatory proteins programmed death ligand-1 (PD-L1) and indolamine 2,3-dioxygenase (IDO). Also provided are nucleic acid constructs encoding said fusion proteins, cells comprising said nucleic acid constructs, and methods of transplanting said cells into a subject.
    Type: Application
    Filed: May 17, 2022
    Publication date: July 25, 2024
    Inventors: Jacques GALIPEAU, Pradyut PAUL
  • Publication number: 20240245731
    Abstract: A sterile micronized composition prepared from intact human placental tissue for wound healing. The sterile micronized composition includes micronized human amnion; micronized human chorion; and micronized human intermediate spongy layer. In certain aspects, the composition is prepared from intact placental tissue comprising a human amnion layer, human chorion layer, and an intact human intermediate spongy layer positioned between the human amnion layer and human chorion layer such that immediately before micronization the human amnion layer and the human chorion layer are not separated from one another.
    Type: Application
    Filed: March 1, 2024
    Publication date: July 25, 2024
    Inventors: Jason V. MATUSZEWSKI, Wendy W. Weston
  • Publication number: 20240245732
    Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 19, 2024
    Publication date: July 25, 2024
    Applicants: UNIVERSITÉ DE LORRAINE, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY
    Inventors: Danièle BENSOUSSAN, Sébastien GIBOT, Loïc REPPEL, Caroline LAROYE, Amir BOUFENZER, Léonore AVERCENC, Céline HUSELSTEIN
  • Publication number: 20240245733
    Abstract: Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.
    Type: Application
    Filed: February 7, 2024
    Publication date: July 25, 2024
    Inventors: Casey Ward, Qizhi TANG, Peter STOCK, Gaetano FALEO, Gopika NAIR, Matthias HEBROK, Wenhan CHANG, Thuy VO, Jeffrey A. BLUESTONE, Elenora DE KLERK
  • Publication number: 20240245734
    Abstract: Provided is a composition in a form of powder, granule, solution, gel, or capsule and including an effective amount of Lacticaseibacillus Paracasei TC1077 deposited under an accession number of DSM 34374 for inhibiting acne, inhibiting bacteria, inhibiting inflammation, strengthening skin structure, improving skin moisture, reducing skin wrinkles, relieving skin dryness, itchiness, and redness, boosting immunity, or promoting defecation. Also provided is a method for inhibiting acne, inhibiting bacteria, inhibiting inflammation, strengthening skin structure, improving skin moisture, reducing skin wrinkles, relieving skin dryness, itchiness, and redness, boosting immunity, or promoting defecation by using the Lacticaseibacillus Paracasei TC1077 or metabolites thereof.
    Type: Application
    Filed: January 15, 2024
    Publication date: July 25, 2024
    Inventors: YUNG-HSIANG LIN, CHU-HAN HUANG
  • Publication number: 20240245735
    Abstract: The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders.
    Type: Application
    Filed: August 2, 2023
    Publication date: July 25, 2024
    Inventors: Heli Putaala, Sofia Forssten, Sampo Lahtinen, Arthur Ouwehand, Jaana Mättö, Harri Mäkivuokko, Janne Nikkilä